Explain that clozapine carries risks including agranulocytosis (which requires regular blood monitoring through the REMS program), metabolic syndrome, myocarditis, seizures at higher doses.
This is correct. The PMHNP should provide a balanced, honest disclosure of clozapine's risks — including agranulocytosis (requiring REMS monitoring), metabolic syndrome, myocarditis, seizure risk, and sedation — while also explaining that clozapine is the gold standard for treatment-resistant schizophrenia and that the monitoring protocol is specifically designed to detect complications early. This balanced approach respects patient autonomy while providing the context needed for informed decision-making.